NovaBay Pharmaceuticals (NYSE:NBY) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Saturday morning. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Price Performance

Shares of NYSE NBY opened at $0.53 on Friday. The stock has a fifty day moving average price of $0.89 and a 200 day moving average price of $2.55. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $17.74. The company has a market cap of $573,351.80, a PE ratio of 0.00 and a beta of 0.73.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 744.33% and a negative net margin of 91.86%. The company had revenue of $2.40 million for the quarter. Analysts anticipate that NovaBay Pharmaceuticals will post -0.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Armistice Capital LLC acquired a new position in NovaBay Pharmaceuticals, Inc. (NYSE:NBY) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned approximately 11.01% of NovaBay Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.